Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allergies Therapy
Studies conducted at University of Perugia on allergies therapy recently published
July 10th, 2007
Scientists discuss in "Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy" new findings in allergies. "Glucocorticoid-induced tumor necrosis factor receptor (GITR) on T cells and its natural ligand, GITRL, on accessory cells contribute to the control of immune homeostasis. Here we show that reverse signaling through GITRL after engagement by soluble GITR initiates the immunoregulatory pathway of tryptophan catabolism in mouse plasmacytoid dendritic cells, by means of noncanonical NF-kappaB-dependent induction of indoleamine 2,3-dioxygenase (IDO)," scientists in Perugia, Italy report. "The synthetic glucocorticoid dexamethasone...
Source: Drug Law Weekly (2007-07-10)
|
